The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.

[1]  S. Otton,et al.  Sparteine oxidation polymorphism in Denmark. , 2009, Acta pharmacologica et toxicologica.

[2]  A. S. Gross,et al.  Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. , 1989, British journal of clinical pharmacology.

[3]  C. Alm,et al.  Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in luman beings , 1989, Clinical pharmacology and therapeutics.

[4]  A. S. Gross,et al.  The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide , 1989, Clinical pharmacology and therapeutics.

[5]  A. Rane,et al.  Dextromethorphan: polymorphic serum pattern of the O-demethylated and didemethylated metabolites in man. , 1989, British journal of clinical pharmacology.

[6]  É. Zarifian,et al.  Substantial rise in sparteine metabolic ratio during haloperidol treatment. , 1989, British journal of clinical pharmacology.

[7]  R. Branch,et al.  Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities , 1989, Clinical pharmacology and therapeutics.

[8]  P. Dayer,et al.  Dextromethorphan O‐demethylation in liver microsomes as a prototype reaction to monitor cytochrome P‐450 db1 activity , 1989, Clinical pharmacology and therapeutics.

[9]  J. Moncrieff,et al.  Metoprolol α-Hydroxylation Polymorphism in the San Bushmen of Southern Africa , 1989 .

[10]  T. Kronbach,et al.  In vitro characterization of the human cytochrome P‐450 involved in polymorphic oxidation of propafenone , 1989, Clinical pharmacology and therapeutics.

[11]  R. Huupponen,et al.  Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio. , 1988, British journal of clinical pharmacology.

[12]  M. Eichelbaum,et al.  Is there a genetic factor in flecainide toxicity? , 1988, BMJ.

[13]  W. Bennett.  Guide to Drug Dosage in Renal Failure , 1988, Clinical pharmacokinetics.

[14]  B. Woggon,et al.  Importance of Oxidative Polymorphism on Clinical Efficacy and Side-Effects of Imipramine - A Retrospective Study , 1988, Pharmacopsychiatry.

[15]  U. Meyer,et al.  Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism. , 1988, Biochemical pharmacology.

[16]  A. Somogyi,et al.  POLYMORPHIC O-DEMETHYLATION OF CODEINE , 1988, The Lancet.

[17]  L. Bertilsson,et al.  Polymorphic debrisoquin hydroxylation in 757 Swedish subjects , 1988, Clinical pharmacology and therapeutics.

[18]  T. D. Arias,et al.  A preliminary note on the transient polymorphic oxidation of sparteine in the Ngawbé Guaymí Amerindians: A case of genetic divergence with tentative phylogenetic time frame for the pathway , 1988, Clinical pharmacology and therapeutics.

[19]  A. Llerena,et al.  Debrisoquin oxidation polymorphism in a Spanish population , 1988, Clinical pharmacology and therapeutics.

[20]  R. Skoda,et al.  Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[21]  R. Dahlqvist,et al.  Inhibition of desipramine 2‐hydroxylation by quinidine and quinine , 1988, Clinical pharmacology and therapeutics.

[22]  J. Moncrieff,et al.  Polymorphism of the 4-Hydroxylation of Debrisoquine in the San Bushmen of Southern Africa , 1988, Human toxicology.

[23]  T. Leemann,et al.  Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). , 1988, Biochemical and biophysical research communications.

[24]  R. Barrantes,et al.  The oxidative metabolism of sparteine in the Cuna Amerindians of Panama: Absence of evidence for deficient metabolizers , 1988, Clinical pharmacology and therapeutics.

[25]  K. Brøsen,et al.  First‐pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype , 1988, Clinical pharmacology and therapeutics.

[26]  D. Nebert,et al.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism , 1988, Nature.

[27]  L. Bertilsson,et al.  LOW FREQUENCY OF SLOW DEBRISOQUINE HYDROXYLATION IN A NATIVE CHINESE POPULATION , 1987, The Lancet.

[28]  D. Trenk,et al.  Drug interaction between propafenone and metoprolol. , 1987, British journal of clinical pharmacology.

[29]  L. Bertilsson,et al.  Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. , 1987, Pharmacology & toxicology.

[30]  D. Roden,et al.  Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. , 1987, Circulation.

[31]  M. Eichelbaum,et al.  Evidence for polymorphic oxidation of sparteine in Japanese subjects. , 1987, British journal of clinical pharmacology.

[32]  A. Boobis,et al.  Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. , 1986, British journal of clinical pharmacology.

[33]  K. Brøsen.  Sparteine oxidation polymorphism in Greenlanders living in Denmark. , 1986, British journal of clinical pharmacology.

[34]  G. Tucker,et al.  Metoprolol and debrisoquin metabolism in nigerians: Lack of evidence for polymorphic oxidation , 1986, Clinical pharmacology and therapeutics.

[35]  K. Róna,et al.  [A survey of debrisoquin hydroxylation polymorphism]. , 1986, Orvosi hetilap.

[36]  R. Lindberg,et al.  Inhibitory effects of neuroleptics on debrisoquine oxidation in man. , 1986, British journal of clinical pharmacology.

[37]  M. Eichelbaum,et al.  The influence of enzyme induction on polymorphic sparteine oxidation. , 1986, British journal of clinical pharmacology.

[38]  D. Berry,et al.  Pharmacodynamics and side effects of flecainide acetate , 1986, Clinical pharmacology and therapeutics.

[39]  G. Shenfield,et al.  Debrisoquine oxidation in an Australian population. , 1986, British journal of clinical pharmacology.

[40]  C Skoda,et al.  The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.

[41]  T. Shimada,et al.  Human-liver cytochromes P-450 involved in polymorphisms of drug oxidation. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.

[42]  M. Eichelbaum,et al.  The genetic polymorphism of sparteine metabolism. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.

[43]  D. Roden,et al.  Co‐inheritance of the polymorphic metabolism of encainide and debrisoquin , 1986, Clinical pharmacology and therapeutics.

[44]  J. Bircher,et al.  Polymorphic dextromethorphan metabolism: Co‐segregation of oxidative O‐demethylation with debrisoquin hydroxylation , 1985, Clinical pharmacology and therapeutics.

[45]  R. Branch,et al.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations , 1985, Clinical pharmacology and therapeutics.

[46]  J. Lindsten,et al.  A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin , 1985, Clinical pharmacology and therapeutics.

[47]  J. J. Fleming,et al.  Pharmacokinetics and beta‐blocking effects of timolol in poor and extensive metabolizers of debrisoquin , 1985, Clinical pharmacology and therapeutics.

[48]  G McKay,et al.  Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin , 1985, Clinical pharmacology and therapeutics.

[49]  T. Henthorn,et al.  Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. , 1985, Biochemical pharmacology.

[50]  K. Antonin,et al.  Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development. , 1985, British journal of clinical pharmacology.

[51]  L. Bertilsson,et al.  Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio. , 1985, British journal of clinical pharmacology.

[52]  M. Eichelbaum,et al.  Dissociation of co‐regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians , 1985, Clinical pharmacology and therapeutics.

[53]  G. Tucker,et al.  Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. , 1985, British journal of clinical pharmacology.

[54]  H. Waal-Manning,et al.  Adverse effects from metoprolol are not generally associated with oxidation status. , 1984, British journal of clinical pharmacology.

[55]  G. Wilkinson,et al.  Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism , 1984, Clinical pharmacology and therapeutics.

[56]  G. Alván,et al.  Relationship of N‐demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism , 1984, Clinical pharmacology and therapeutics.

[57]  G. Pfaff,et al.  DEXTROMETHORPHANAS A SAFE PROBE FOR DEBRISOQUINE HYDROXYLATION POLYMORPHISM , 1984, The Lancet.

[58]  L. Bertilsson,et al.  Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjects , 1984, Clinical pharmacology and therapeutics.

[59]  W. Kalow,et al.  A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase. , 1984, Canadian journal of physiology and pharmacology.

[60]  G. Wilkinson,et al.  Polymorphic ability to metabolize propranolol alters 4‐hydroxypropranolol levels but not beta blockade , 1984, Clinical pharmacology and therapeutics.

[61]  E. Williams.  A Classification of Antiarrhythmic Actions Reassessed After a Decade of New Drugs , 1984 .

[62]  C. Regårdh,et al.  Interindividual variations in metoprolol metabolism--some clinical and other observations. , 1984, British journal of clinical pharmacology.

[63]  D. Willard,et al.  Protecting the poor metaboliser‐from what? [letter] , 1984 .

[64]  D. Roden,et al.  Influence of genetic polymorphism on the metabolism and disposition of encainide in man. , 1984, The Journal of pharmacology and experimental therapeutics.

[65]  K. Okumura,et al.  Quinidine‐induced rise in ajmaline plasma concentration , 1984, The Journal of pharmacy and pharmacology.

[66]  D. Evans,et al.  Polymorphic hydroxylation of perhexiline maleate in man. , 1984, Journal of medical genetics.

[67]  W. Kalow,et al.  Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. , 1984, Life sciences.

[68]  G. Tucker,et al.  Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers , 1983, Clinical pharmacology and therapeutics.

[69]  L. Bertilsson,et al.  Amitriptyline metabolism: Relationship to polymorphic debrisoquine hydroxylation , 1983, Clinical pharmacology and therapeutics.

[70]  J. Idle,et al.  The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions. , 1983, Journal of medical genetics.

[71]  G. Pfaff,et al.  Inter-individual variation in the metabolism of dextromethorphan , 1983 .

[72]  W. Kalow,et al.  Comparative pharmacogenetics of sparteine and debrisoquine , 1983, Clinical pharmacology and therapeutics.

[73]  W. Kalow,et al.  Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs. , 1983, Life sciences.

[74]  B. Dick,et al.  [Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population]. , 1982, Schweizerische medizinische Wochenschrift.

[75]  J. Idle,et al.  Genetic polymorphism of phenformin 4‐hydroxylation , 1982, Clinical pharmacology and therapeutics.

[76]  G. Alván,et al.  HIGH PLASMA CONCENTRATIONS OF β-RECEPTOR BLOCKING DRUGS AND DEFICIENT DEBRISOQUINE HYDROXYLATION , 1982, The Lancet.

[77]  J. Idle,et al.  Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. , 1982, British medical journal.

[78]  W. Kalow,et al.  Sparteine metabolism in Canadian Caucasians , 1982, Clinical pharmacology and therapeutics.

[79]  M. Åsberg,et al.  SLOW HYDROXYLATION OF NORTRIPTYLINE AND CONCOMITANT POOR DEBRISOQUINE HYDROXYLATION: CLINICAL IMPLICATIONS , 1981, The Lancet.

[80]  L. Bertilsson,et al.  Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. , 1980, Life sciences.

[81]  J. Idle,et al.  A study of the debrisoquine hydroxylation polymorphism in a Nigerian population. , 1980, Xenobiotica; the fate of foreign compounds in biological systems.

[82]  J. Idle,et al.  The polymorphic 4-hydroxylation of debrisoquine in a Saudi arab population. , 1980, Xenobiotica; the fate of foreign compounds in biological systems.

[83]  P. Jatlow,et al.  Neuroloeptic effect on desipramine steady-state plasma concentratins. , 1980, The American journal of psychiatry.

[84]  J. Idle,et al.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. , 1980, Journal of medical genetics.

[85]  J. Idle,et al.  Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians , 1979, Clinical pharmacology and therapeutics.

[86]  J. Idle,et al.  Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine. , 1979, Xenobiotica; the fate of foreign compounds in biological systems.

[87]  J. Idle,et al.  Polymorphism of carbon oxidation of drugs and clinical implications. , 1978, British medical journal.

[88]  J. Idle,et al.  Hypotensive response to debrisoquine and hydroxylation phenotype. , 1978, Life sciences.

[89]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[90]  G. Tucker,et al.  Recurrent breast cancer treated with the antioestrogen tamoxifen: correlation between hormonal changes and clinical course. , 1977, British medical journal.

[91]  L. Gram,et al.  Drug Interaction: Inhibitory Effect of Neuroleptics on Metabolism of Tricyclic Antidepressants in Man , 1972, British medical journal.

[92]  F. Sjöqvist,et al.  Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. , 1967, Life sciences.

[93]  R. C. Benson,et al.  Sparteine sulfate: a potent, capricious oxytocic. , 1966, American journal of obstetrics and gynecology.

[94]  R. Skoda,et al.  The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms. , 1990, Pharmacology & therapeutics.

[95]  D. Brazier,et al.  Cardiovascular responses to metipranolol and timolol eyedrops in healthy volunteers. , 1989, British journal of clinical pharmacology.

[96]  M. Lennard.  The polymorphic oxidation of beta-adrenoceptor antagonists. , 1989, Pharmacology & therapeutics.

[97]  L. Bertilsson,et al.  Rapid conjugation in an extremely rapid hydroxylator of debrisoquine: a case report supporting a coregulation of certain phase I and II metabolic reactions. , 1988, Therapeutic drug monitoring.

[98]  L. Bertilsson,et al.  Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. , 1985, Therapeutic drug monitoring.

[99]  J. Idle,et al.  Prediction of subclinical perhexiline neuropathy in a patient with inborn error of debrisoquine hydroxylation. , 1983, American heart journal.

[100]  B. Schwartzkopff,et al.  Comparison of tocainide and prajmalium bitartrate for the treatment of ventricular arrhythmias. , 1983, Arzneimittel-Forschung.

[101]  J. Idle,et al.  A population and familial study of the defective alicyclic hydroxylation of debrisoquine among Egyptians. , 1979, Xenobiotica; the fate of foreign compounds in biological systems.

[102]  Gram Lf.  Effects of perphenazine on imipramine metabolism in man. , 1975 .